Core Insights - Innovent Biologics is set to present multiple clinical study results of mazdutide at the American Diabetes Association's 84th Scientific Sessions, highlighting its significance in obesity treatment [1] - Mazdutide is the first GLP-1R/GCGR dual agonist to succeed in a Phase 3 registration study for overweight and obesity, indicating its potential as a weight management option [1][2] Group 1: Clinical Studies and Presentations - The first Phase 3 study of mazdutide in Chinese adults with obesity and overweight (GLORY-1) will be presented, along with an exploratory analysis on liver steatosis and a Phase 2 study of mazdutide 9 mg [1] - The presentation details include an oral presentation on the efficacy and safety of mazdutide, scheduled for June 23, 2024, and two poster presentations [1] Group 2: Drug Development and Mechanism - Mazdutide (IBI362) is a GLP-1R and GCGR dual agonist developed under an exclusive license agreement with Eli Lilly, showing robust weight loss and glucose-lowering effects in clinical studies [2] - The drug has demonstrated improvements in various cardio-metabolic indicators, including waist circumference, blood lipids, and liver fat content [2] Group 3: Regulatory Progress - The first New Drug Application (NDA) for mazdutide was accepted by the CDE of the NMPA of China for chronic weight management in adults with obesity or overweight in February 2024 [3] Group 4: Company Overview - Innovent Biologics, founded in 2011, focuses on developing high-quality biologics for various diseases, with 10 products currently on the market and several in clinical trials [4] - The company collaborates with over 30 global healthcare leaders, including Eli Lilly and Roche, to advance its biopharmaceutical offerings [5]
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions